OVID
Ovid Therapeutics Inc.Company Information
- Company Name
- Ovid Therapeutics Inc.
- CIK
- CIK0001636651
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- OVID: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- OVID
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-27
- Last sale
- 2026-02-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 29,378
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 147,308,977
- Shares outstanding
- 0
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 94 | 13 | 21 | 28 | 21 | 26 | 15 | 30 | 31 | 27 | 57 | ||||||
| Available For Sale Securities Debt Securities Current | 106 | 61 | 56 | 5 | 10 | 22 | 27 | 48 | 47 | 59 | 79 | 30 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 5 | 5 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 4 | 5 | ||||||
| Assets Current | 124 | 160 | 74 | 29 | 42 | 46 | 56 | 66 | 81 | 93 | 110 | 92 | ||||||
| Long Term Investments | - | - | - | 21 | 21 | 21 | 21 | 21 | 21 | 22 | 18 | 16 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 53 | 10 | 21 | - | - | - | 0 | - | - | - | - | - | ||||||
| Equity Securities Without Readily Determinable Fair Value Amount | 43 | 42 | 42 | - | - | - | 21 | - | - | - | - | - | ||||||
| Restricted Cash | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 11 | 11 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 14 | 14 | 14 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 232 | 226 | 151 | 64 | 77 | 82 | 92 | 103 | 118 | 132 | 144 | 125 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 9 | 2 | 2 | 4 | 2 | 3 | 3 | 5 | 4 | 4 | 1 | ||||||
| Accrued Liabilities Current | 4 | 5 | 5 | 3 | 3 | 6 | 6 | 8 | 8 | 4 | 7 | 6 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Contract With Customer Liability | - | - | - | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 10 | 16 | 8 | 7 | 9 | 9 | 11 | 12 | 14 | 9 | 11 | 9 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 11 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 15 | ||||||
| Liabilities | 22 | 27 | 20 | 19 | 22 | 22 | 24 | 26 | 29 | 53 | 56 | 24 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 564 | 537 | 452 | 376 | 375 | 374 | 372 | 371 | 370 | 368 | 366 | 364 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -354 | -339 | -322 | -331 | -319 | -315 | -304 | -295 | -281 | -290 | -278 | -263 | ||||||
| Stockholders Equity | 210 | 198 | 131 | 45 | 56 | 59 | 68 | 76 | 89 | 78 | 88 | 101 | ||||||
| Liabilities And Stockholders Equity | 232 | 226 | 151 | 64 | 77 | 82 | 92 | 103 | 118 | 132 | 144 | 125 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 315 | 315 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | ||||||
| Common Stock Shares Issued | 185 | 167 | 130 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | ||||||
| Shares Outstanding | 185 | 167 | 130 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 71 | ||||||
| Preferred Stock Shares Authorized | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOvid Therapeutics Inc. (OVID) — SEC Financial Statements & Analysis
Ovid Therapeutics Inc. (OVID) is a pharmaceutical preparations company, incorporated in DE. Ovid Therapeutics Inc. trades on Nasdaq as: OVID. Ovid Therapeutics Inc. (OVID)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Ovid Therapeutics Inc. carries a market cap of $496.99M, a P/E ratio of -14.41x, a P/B ratio of 2.37x, a P/S ratio of 313.96x, an enterprise value of $483.73M, and an EV/EBITDA multiple of -8.30x. On profitability, it posts an operating margin of -3686.67%, a net margin of -2178.90%, a Return on Equity (ROE) of -25.97%, a Return on Assets (ROA) of -22.30%, and a Return on Invested Capital (ROIC) of -52.52%. Per share, it reports EPS of $-0.19, diluted EPS of $-14871.05, free cash flow per share of $-0.30, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -76.20% year-over-year, net income growth of -9.66% year-over-year, and EPS growth of -100.00% year-over-year. On the balance sheet, it maintains a current ratio of 12.39x, a quick ratio of 11.75x, working capital of $113.64M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, free cash flow of $-54.77M (TTM), and net debt of $-13.26M. Figures sourced from SEC EDGAR.
- Market Cap
- $496.99M
- P/E TTM
- -14.41x
- EPS TTM
- $-0.19
- P/B TTM
- 2.37x
- ROE TTM
- -25.97%
- ROA TTM
- -22.30%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-54.77M
- Net Revenue TTM Growth 1Y
- -76.20%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Ovid Therapeutics Inc. in?
Ovid Therapeutics Inc. (OVID) operates in the Pharmaceutical Preparations industry.
What exchange does OVID trade on?
Ovid Therapeutics Inc. (OVID) trades on the Nasdaq.
Where is Ovid Therapeutics Inc. incorporated?
Ovid Therapeutics Inc. is incorporated in DE.
When was Ovid Therapeutics Inc. (OVID)'s most recent SEC filing?
Ovid Therapeutics Inc. (OVID)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is OVID's market cap?
Ovid Therapeutics Inc. (OVID) has a market capitalization of $496.99M as of 2026-06-30.
What is OVID's EPS (earnings per share)?
Ovid Therapeutics Inc. (OVID)'s trailing twelve month EPS is $-0.19 as of 2026-06-30.
What is OVID's ROE (return on equity)?
Ovid Therapeutics Inc. (OVID)'s trailing twelve month Return on Equity (ROE) is -25.97% as of 2026-06-30.
What is OVID's ROA (return on assets)?
Ovid Therapeutics Inc. (OVID)'s trailing twelve month Return on Assets (ROA) is -22.30% as of 2026-06-30.
What is OVID's ROIC (return on invested capital)?
Ovid Therapeutics Inc. (OVID)'s trailing twelve month Return on Invested Capital (ROIC) is -52.52% as of 2026-06-30.
What is OVID's EV/EBITDA?
Ovid Therapeutics Inc. (OVID)'s trailing twelve month EV/EBITDA is -8.30x as of 2026-06-30.